Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

Corporate Presentation Feb. 2026

FY2025 Presentation

Consolidated Financial Results for the Year Ended December 31, 2025

Updates from the ongoing Phase 1b study and new preclinical findings of the next-generation BTK inhibitor, docirbrutinib (AS-1763), presented at the 67th American Society of Hematology Annual Meeting

FY2025 Q3 Presentation

Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2025

Carna announces acceptance of two posters on docirbrutinib for presentation at the 67th ASH Annual Meeting

FY2025 Q2 Presentation